In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors
- PMID: 10395861
- DOI: 10.1086/314871
In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors
Abstract
Highly active antiretroviral therapy that includes human immunodeficiency virus (HIV) aspartyl protease inhibitors (PIs) causes a decline in the incidence of some opportunistic infections in AIDS, and this decline is currently attributed to the restoration of specific immunity. The effect of two PIs (indinavir and ritonavir) on the enzymatic activity of a secretory aspartyl protease (Sap) of Candida albicans (a major agent of mucosal disease in HIV-infected subjects) and on growth and experimental pathogenicity of this fungus was evaluated. Both PIs strongly (>/=90%) and dose dependently (0.1-10 microM) inhibited Sap activity and production. They also significantly reduced Candida growth in a nitrogen-limited, Sap expression-dependent growth medium and exerted a therapeutic effect in an experimental model of vaginal candidiasis, with an efficacy comparable to that of fluconazole. Thus, besides the expected immunorestoration, patients receiving PI therapy may benefit from a direct anticandidal activity of these drugs.
Comment in
-
Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection.J Infect Dis. 2000 Feb;181(2):812-3. doi: 10.1086/315290. J Infect Dis. 2000. PMID: 10669393 No abstract available.
-
Changes in oropharyngeal colonization and infection by Candida albicans in human immunodeficiency virus-infected patients.J Infect Dis. 2001 Jan 15;183(2):355-356. doi: 10.1086/317920. J Infect Dis. 2001. PMID: 11120936 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous